Evidence map›Paper›PMID 36371552›Full record

ArticleMolecular biology reports2023

The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.

Reem Nabil, Naglaa M Hassan, Mona S Abdellateif, Rania M Gawdat, Samar Sami Elshazly

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. CanPharmaceuticals (Basel, Switzerland) · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Reem NabilClinical pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Naglaa M HassanClinical pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Mona S AbdellateifMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo University, Giza, Egypt. mona-sayed@cu.edu.eg.
Rania M GawdatClinical and chemical pathology department, Faculty of medicine, Beni Suef university, Beni Suef, Egypt.
Samar Sami ElshazlyClinical pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Cairo University · EGBeni-Suef University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimwas to assess the role of C-KIT, TET1 and TET2 expression in the diagnosis and prognosis of acute myeloblastic leukemia (AML).

methodsThe expression levels of C-KIT, TET1 and TET2 were assessed in the bone marrow (BM) aspirate of 152 AML patients compared to 20 healthy control using quantitative real-time polymerase chain reaction (qRT-PCR). Data were correlated with the clinico-pathological features of the patients, response to treatment, disease-free survival (DFS), and overall survival (OS) rates.

resultsC-KIT, TET1 and TET2 were significantly upregulated in AML patients [0.25 (0-11.6), 0.0113 (0-3.301), and 0.07 (0-4); respectively], compared to the control group [0.013 (0.005-0.250), P < 0.001, 0.001 (0-0.006), P < 0.001, and 0.02 (0.008-0.055), P = 0.019; respectively]. The sensitivity, specificity, and area under curve of of C-KIT were (48.7%, 100%, 0.855; respectively, P = 0.001), and that of TET1 were (63.4%, 100%, 0.897; respectively, P = 0.001), while that of TET2 were (56.8%, 100%, 0.766; respectively, P = 0.019). When combining the three markers, the sensitivity was 77.5%, however it reached the highest sensitivity (78.6%) and specificity (100%) when combining both c-KIT + TET1 together for the diagnosis of AML. C-KIT overexpression associated with shorter DFS (P = 0.05) and increased incidence of relapse (P = 0.019). Lymph nodes involvement [HR = 2.200, P = 0.005] is an independent risk factor for shorter OS rate of AML patients. Increased BM blast % [HR = 7.768, P = 0.002], and FLT3-ITD mutation [HR = 2.989, P = 0.032] are independent risk factors for shorter DSF rate of the patients.

conclusionC-KIT, TET1, and TET2 could be used as possible useful biomarkers for the diagnosis of AML.

Indexed as

DioxygenasesLeukemia, Myeloid, AcuteDNA-Binding ProteinsGene ExpressionHumansMixed Function OxygenasesMutationPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins c-kitReceptor Protein-Tyrosine KinasesDioxygenasesDNA-Binding ProteinsMixed Function OxygenasesProto-Oncogene ProteinsProto-Oncogene Proteins c-kitReceptor Protein-Tyrosine KinasesTET1 protein, humanTET2 protein, humanAMLC-KITTET1TET2

Identifiers

PMID36371552
PMCPMC9884250
OpenAlexW4308842549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.